GJGary P. Jeffrey

Gary P. Jeffrey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gary P. Jeffrey has a total of 68 co-authors. Here are the top co-authors by number of shared publications:

  • Gerry MacQuillan

    School of Medicine and Pharmacology The University of Western Australia Perth Western Australia Australia

    6 shared publications
  • Leon Anton Adams

    Medical School University of Western Australia Nedlands Western Australia Australia

    5 shared publications
  • Yi Huang

    School of Medicine and Pharmacology, University of Western Australia, Perth, Australia; Department of Hepatology, Sir Charles Gairdner Hospital, Perth, Australia

    5 shared publications
  • John Joseph

    Department of Biochemistry PathWest Laboratory Medicine Perth Western Australia Australia

    4 shared publications
  • Leon A Adams

    School of Medicine and Pharmacology The University of Western Australia Perth Western Australia Australia

    4 shared publications
  • George Garas

    Department of Hepatology Sir Charles Gairdner Hospital Perth Western Australia Australia

    3 shared publications

Latest Publications

  • Open Access

    Internal validation of the Hepascore and Liver Outcome Score for predicting clinical outcomes in autoimmune hepatitis and primary sclerosing cholangitis: a multi-centre study

    by Dujinthan Jayabalan, Luis Calzadilla-Bertot, Yi Huang, Wendy Cheng, Simon Hazeldine, Briohny W. Smith, Gerry C. MacQuillan, Michael C. Wallace, George Garas, Leon A. Adams, et al.

  • Open Access

    Higher Overall Intakes Are the Defining Feature of Dietary Intakes in NAFLD and Compared to the General Population

    by Catherine Properzi, Leon A. Adams, Johnny Lo, Jill L. Sherriff, Gary P. Jeffrey, Therese A. O’sullivan

    We aimed to compare the dietary intakes of Australian patients with non-alcoholic fatty liver disease (NAFLD) to general Australian population intake data and determine whether the intake of any nutrient or food group was able to predict the degree of steatosis. Dietary data from fifty adult patients with NAFLD were compared to intake data from the Australian Health Survey for energy, macronutrients, fat sub-types, alcohol, iron, folate, sugar, fibre, sodium and caffeine. Linear regression models adjusting for potential confounders (age, sex, physical activity and body mass index) were used to examine predictive relationships between hepatic steatosis (quantified via magnetic resonance spectroscopy) and dietary components. The mean percentage differences between NAFLD and Australian usual intakes were significant for energy, protein, total fat, saturated fat, monounsaturated and polyunsaturated fats (all p < 0.001). The contribution of fat and protein to total energy intake was significantly higher in the NAFLD cohort (p < 0.05). No individual nutrients or food groups were strongly related to hepatic fat in the adjusted models. Higher overall consumption appears to be a major feature of dietary intake in NAFLD when compared to the general population. A whole-diet approach to NAFLD treatment and prevention is likely to be more effective than focusing on single food components.


  • Open Access

    Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease

    by Luis C. Bertot, Gary P. Jeffrey, Bastiaan de Boer, Zhengyi Wang, Yi Huang, George Garas, Gerry MacQuillan, Michael Wallace, Briohny W. Smith, Leon A. Adams

    Background Non-invasive tests are widely used to diagnose fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), however, the optimal method remains unclear. We compared the accuracy of simple serum models, a serum model incorporating direct measures of fibrogenesis (Hepascore), and Fibroscan®, for detecting fibrosis in NAFLD. Methods NAFLD patients undergoing liver biopsy were evaluated with Hepascore, NAFLD Fibrosis Score (NFS), FIB-4 and AST-platelet ratio index (APRI), with a subset (n = 131) undergoing Fibroscan®. Fibrosis on liver biopsy was categorized as advanced (F3–4) or cirrhosis (F4). Accuracy was determined by area under receiving operating characteristic curves (AUC). Indeterminate ranges were calculated using published cut-offs. Results In 271 NAFLD patients, 83 (31%) had F3–4 and 47 (17%) cirrhosis. 6/131 (4%) had an unreliable Fibroscan®. For the detection of advanced fibrosis, the accuracy of Hepascore (AUC 0.88) was higher than FIB-4 (0.73), NFS (0.72) and APRI (0.69) (p < 0.001 for all). Hepascore had similar accuracy to Fibroscan® (0.80) overall, but higher accuracy in obese individuals (0.91 vs 0.80, p = 0.001). Hepascore more accurately identified patients with cirrhosis than APRI (AUC 0.85 vs 0.71, p = 0.01) and NFS (AUC 0.73, p = 0.01) but performed similar to FIB-4 and Fibroscan®. For the determination of F3-4, the proportion of patients in indeterminate area was lower for Hepascore (4.8%), compared to FIB-4 (42%), NFS (36%) and APRI (44%) (p < 0.001 for all). Conclusions Hepascore has greater accuracy and a lower indeterminate range than simple serum fibrosis tests for advanced fibrosis in NAFLD, and greater accuracy than Fibroscan® in obese individuals.


  • Open Access

    Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0

    by Savio G. Barreto, Simone I. Strasser, Geoffrey W. McCaughan, Michael A. Fink, Robert Jones, John McCall, Stephen Munn, Graeme A. Macdonald, Peter Hodgkinson, Gary P. Jeffrey, et al.

    Background: Expansion in liver transplantation (LT) criteria for HCC from Milan to UCSF has not adversely impacted overall survival, prompting further expansion towards Metroticket 2.0 (MT2). In this study, we compared patient survival post-transplant before and after 2007 and long-term outcomes for LT within Milan versus UCSF criteria (to determine the true benefit of the expansion of criteria) and retrospectively validated the MT2 criteria. Methods: Retrospective analysis of ANZLITR (including all patients transplanted for HCC since July 1997). The entire cohort was divided based on criteria used at the time of listing, namely, Milan era (1997–2006) and the UCSF era (2007–July 2015). Results: The overall 5- and 10-year cumulative survival rates for the entire cohort of 691 patients were 78% and 69%, respectively. Patients transplanted in UCSF era had significantly higher 5- and 10-year survival rates than in the Milan era (80% vs. 73% and 72% vs. 65%, respectively; p = 0.016). In the UCSF era, the 5-year survival rate for patients transplanted within Milan criteria was significantly better than those transplanted outside Milan but within UCSF criteria (83% vs. 73%; p < 0.024). Patients transplanted within the MT2 criteria had a significantly better 5- and 10-year survival rate as compared to those outside the criteria (81% vs. 64% and 73% vs. 50%, respectively; p = 0.001). Conclusion: Overall survival following LT for HCC has significantly improved over time despite expanding criteria from Milan to UCSF. Patients fulfilling the MT2 criteria have a survival comparable to the UCSF cohort. Thus, expansion of criteria to MT2 is justifiable.


  • Open Access

    Changes in the Epidemiology of Hepatobiliary Disease Complicating Type 2 Diabetes over 25 Years: The Fremantle Diabetes Study

    by Timothy M.E. Davis, Kirsten E. Peters, S. A. Paul Chubb, Leon A. Adams, Gary P. Jeffrey, Wendy A. Davis

    Objective: To determine whether the incidence/outcome of hepatobiliary disease (HBD) has increased over recent decades in community-based Australians with and without type 2 diabetes (T2D). Methods: Longitudinal data from the Fremantle Diabetes Study Phase I (FDS1; recruitment 1993–1996; n = 1291 with T2D) and Phase II (FDS2; 2008–2011; n = 1509) were analyzed. Participants with T2D from both Phases were age-, sex-, and postcode-matched 1:4 to people without diabetes. Incident HBD and associated mortality were ascertained from hospitalization, cancer registration, and/or death certification codes. Incidence rates (IRs) and IR ratios (IRRs) for those with versus without diabetes in FDS1 and FDS2 were calculated. Results: HBD IRs for people without diabetes did not change between Phases. The IRR (95% CI) for people with T2D in FDS2 versus FDS1 was 1.30 (1.01–1.68) with the highest IRRs in participants aged <65 years. Non-alcoholic fatty liver disease/steatohepatitis (NAFLD/NASH) events were 54% greater in FDS2 than FDS1 in the presence of greater abdominal adiposity. NAFLD/NASH was coded in one in 11 HBD events in FDS2 and in 10% of HBD deaths (<4% of total mortality). Conclusions: HBD is more frequent in people with versus without T2D and this discrepancy is increasing. Hospitalizations/deaths due to NAFLD/NASH remain uncommon.


  • Open Access

    Hepascore predicts liver outcomes and all‐cause mortality in long‐term methotrexate users: A retrospective cohort study

    by Zhengyi Wang, Yi Huang, Hans Nossent, Jonathan J Chan, Leon A Adams, John Joseph, Wendy Cheng, George Garas, Gerry MacQuillan, Gary P Jeffrey

    Background and aim: Methotrexate (MTX) is routinely used for immunological disorders, and its long‐term use is associated with hepatotoxicity. The aim of this study was to investigate whether a serum liver fibrosis test (Hepascore) predicted the risk of adverse liver‐related outcomes and mortality.Methods: A total of 92 patients in Western Australia who had a long‐term MTX intake history,from 2004 to 2016, were recruited and followed up from the first Hepascore to death or end of the study. Clinical data, all deaths, and liver‐related outcomes (liver‐related death and decompensation) were obtained from hospital, PathWest, and WA Data Linkage Unit databases.Results: Nine deaths and four adverse liver‐related outcomes occurred during the follow up of 354 person‐years. The 5‐year survival was 86.1%. The liver‐related outcome free survival was 95.6%. Baseline Hepascore ≥0.84 was associated with advanced fibrosis on liver biopsy (P = 0.025). A baseline Hepascore ≥0.84 was significantly associated with higher risks for adverse liver‐related outcomes (P < 0.001) and all‐cause mortality (P = 0.001). Cox regression demonstrated that only baseline Hepascore ≥0.84 was independently associated with the increased risk of all‐cause mortality (7.91 [1.52–41.29], P = 0.014). Moreover, any Hepascore ≥0.84 found during follow up was independently associated with the increased risk of all‐cause mortality (86.18 [4.03–1844.83], P = 0.007).Conclusions: This study demonstrated the potential importance of Hepascore monitoring in long‐term MTX users. Patients with a Hepascore higher than 0.84 at any stage had increased mortality, but further studies are required to confirm this finding.


  • Hepatocellular carcinoma surveillance in Australia: time to improve the diagnosis of cirrhosis and use liver ultrasound

    by Gary P Jeffrey, Louisa Gordon, Grant Ramm

    Click on the article title to read more.


  • Liquid Biopsies for Hepatocellular Cancer and Their Potential in Clinical Practice

    by Gary P. Jeffrey, Louisa G. Gordon, Michelle M. Hill, Grant A. Ramm

    Clinicians need to be aware of the powerful new technologies that are being directed toward early diagnosis of hepatocellular carcinoma (HCC). A recent article by Qu C, Wang Y, Wang P, et al. Detection of early‐stage hepatocellular carcinoma in asymptomatic HBsAg‐seropositive individuals by liquid biopsy. Proc Natl Acad Sci U S A. 2019;116:6308‐6312 reported that the presence of somatic mutations and HBV integrations in circulating cell free DNA (cfDNA), the concentration of cfDNA and concentration of protein tumor markers in blood were combined with age and gender to develop a “liquid biopsy” to identify early stage HCC.


  • Long-term Liver-related Outcomes of Patients With Chronic Liver Diseases in Australia

    by Yi Huang, John Joseph, W. Bastiaan de Boer, Wendy Cheng, Leon A. Adams, Gerry MacQuillan, George Garas, Spiro Raftopoulos, Gary P. Jeffrey